IMPLANET Announces Its 2022 Financial Calendar

BORDEAUX, France & BOSTON--(BUSINESS WIRE)-- Regulatory News:

IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specialized in vertebral implants, today announces its schedule for the publication of financial information for 2022Etats-Unis de son expansion commerciale aux Etats-Unis,.

(*): These dates can be subject to modifications. Press releases will be published after market close.

Upcoming financial event:
– 2021 Full-Year Results, on March 15, 2022 after market close.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 29 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.implanet.com.

The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005550/en/

IMPLANET

Ludovic Lastennet, CEO

David Dieumegard, CFO

Tel.: +33 (0)5 57 99 55 55

investors@Implanet.com

NewCap

Investor Relations

Mathilde Bohin

Nicolas Fossiez

Tel.: +33 (0)1 44 71 94 94

implanet@newcap.eu

NewCap

Media Relations

Nicolas Merigeau

Tel.: +33 (0)1 44 71 94 94

implanet@newcap.eu

Source: IMPLANET